A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes

Table 2

Proportions of individual developing diabetes and reverting back to normoglycemic state at 1, 2, and 3 years of follow-up, by treatment groups and the odds ratio (95% CI) of the likelihood of reverting to normoglycemic state and developing diabetes during 3 years of follow-up in the three treatment groups, compared to the conventional+placebo group.

	Conventional lifestyle+placebo	Intensive lifestyle+placebo	Conventional lifestyle+pioglitazone	Intensive lifestyle+pioglitazone
Year 1
	480	490	492	483
Lost to follow-up	88 (18.3)	92 (18.8)	95 (19.3)	91 (18.8)
DM	54 (11.3)	57 (11.6)	48 (9.8)	36 (7.5)
Normal	185 (38.5)	151 (30.8)	188 (38.2)	205 (42.4)
Year 2
	153	190	161	151
Lost to follow-up	51 (33.3)	70 (36.8)	68 (42.2)	43 (28.5)
DM	20 (13.1)	15 (7.9)	15 (9.3)	16 (10.6)
Normal	41 (26.8)	38 (20.0)	32 (19.9)	44 (29.1)
Year 3
	41	67	46	48
Lost to follow-up	18 (43.9)	31 (46.3)	18 (39.1)	25 (52.1)
DM	1 (2.4)	8 (11.9)	9 (19.6)	2 (4.2)
Normal	10 (24.4)	11 (16.4)	3 (6.5)	6 (12.5)
Overall
Normal	236 (60.0)	200 (50.3)	224 (56.6)	255 (65.1)
SHR (95% CI)	Ref	0.61 (0.41, 0.93)	0.82 (0.55, 1.22)	1.15 (0.66, 1.57)
p		0.020	1.00	0.76
DM	76 (11.63)	80 (16.3)	72 (14.4)	54 (11.2)
SHR (95% CI)	Ref	1.00 (0.61, 1.57)	0.83 (0.47, 1.36)	0.55 (0.32, 0.90)
		0.86	0.26	0.024